Illumina, Inc. (NASDAQ:ILMN) Receives $164.65 Average PT from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have earned an average rating of "Hold" from the twenty analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $164.65.

A number of brokerages have recently weighed in on ILMN. Robert W. Baird boosted their price objective on shares of Illumina from $125.00 to $128.00 and gave the company a "neutral" rating in a report on Friday, May 3rd. Stephens reissued an "overweight" rating and issued a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. HSBC cut Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. Scotiabank dropped their target price on Illumina from $185.00 to $176.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the company's stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is currently owned by insiders.

Institutional Trading of Illumina

A number of institutional investors and hedge funds have recently modified their holdings of the stock. abrdn plc boosted its holdings in Illumina by 764.9% in the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company's stock worth $47,206,000 after buying an additional 299,827 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Illumina during the third quarter worth approximately $29,558,000. International Assets Investment Management LLC raised its stake in Illumina by 210.5% in the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company's stock valued at $6,711,000 after purchasing an additional 32,672 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Illumina by 5.9% in the 4th quarter. Victory Capital Management Inc. now owns 122,743 shares of the life sciences company's stock valued at $17,091,000 after purchasing an additional 6,827 shares in the last quarter. Finally, Aquila Investment Management LLC boosted its stake in Illumina by 150.0% during the 4th quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company's stock worth $3,481,000 after purchasing an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 0.5 %

Shares of Illumina stock traded down $0.57 during trading on Wednesday, reaching $115.01. The company's stock had a trading volume of 1,243,697 shares, compared to its average volume of 1,730,134. Illumina has a 1-year low of $89.00 and a 1-year high of $213.91. The company has a 50-day simple moving average of $126.48 and a two-hundred day simple moving average of $126.88. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The company has a market cap of $18.32 billion, a price-to-earnings ratio of -13.97 and a beta of 1.20.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period last year, the business posted $0.08 earnings per share. The firm's revenue was down 1.0% compared to the same quarter last year. As a group, equities analysts forecast that Illumina will post 0.87 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.